News

News

Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region

Tuesday, January 12, 2016

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce its expansion of Phase I-IV clinical trial services into the Asia-Pacific region.

This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.

Pharm-Olam Strengthens Leadership Team with New Chief Financial Officer

Sunday, December 20, 2015

Financial OfficerPharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce the promotion of Natalie Gassen to the position of Chief Financial Officer.

Pharm-Olam International Expands to Larger Facility in Poland

Tuesday, October 13, 2015

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the relocation of its Polish location to a larger office to accommodate for its growing staff.

Pharm-Olam International Opens a New Office in Paris, France; Continues Global Expansion

Thursday, June 11, 2015

HOUSTON, TEXAS – Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the opening of a new, fully-staffed office in Paris, France.

Pharm-Olam Releases Case Study on Automated Sample Retention for BA/BE

Thursday, March 12, 2015

Bioavailability and Bioequivalence (BA/BE) studies require samples of investigational product retained. Typically, this is performed manually and overseen by clinical monitors during site initiation. This manual approach is feasible for limited sites, but larger site numbers make manual retention less feasible. This case study reviews Pharm-Olam's Automated Sample Retention Solution that was used in a recent study.

To read the complete case study click here.

Pharm-Olam completes a Phase III Pulmonary Arterial Hypertension study

Thursday, February 12, 2015

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients.

Pharm-Olam was responsible for:
  • The recruitment of 192 patients
  • Management of 17 sites in Russia, Belarus, and Ukraine
  • All regulatory, project management, and monitoring services

To view the case study and the lessons learned in this study, click here

Pharm-Olam releases a corporate overview video

Monday, January 12, 2015

To learn more about the benefits that Pharm-Olam offers click here to view the video.

Pharm-Olam hosts a webinar to explain how political events are affecting clinical trials in Ukraine

Thursday, November 13, 2014

The Ukraine has been a hot topic in the news due to the recent turmoil in the country. Even during these difficult times, drug development and clinical trials continue to be run in the Ukraine, which boasts recruitment figures at least two times higher than those in the United States and Western Europe.

To view a recording of this webinar, click here

Pharm-Olam International Celebrates 20-Year Anniversary

Tuesday, November 04, 2014

HOUSTON, TEXAS - November 4th, 2014.

Pharm-Olam International Ltd., a multi-national, full-service CRO to biopharmaceutical and device industries is proud to celebrate 20 years of successfully helping our sponsors create a healthier world.

Pharm-Olam completes birch and grass pollen allergy studies

Saturday, February 01, 2014

Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe. With two different allergy indications, Grass Pollen and Birch Pollen, these studies presented some unique challenges.